<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Toribio M</submitter><funding>NICHD NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><pagination>64-73</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9942173</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(1)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Through a survey-based approach, we sought to investigate regional differences in gender-affirming hormone therapy (GAHT) prescribing practices, as well as HIV screening and prevention practices among clinicians providing care to transgender individuals.&lt;h4>Methods&lt;/h4>Our survey was disseminated between December 2019 and January 2021 to clinicians who prescribe GAHT within New England (United States). Between-group differences in GAHT prescribing and HIV screening/prevention practices were evaluated by practice setting and subspecialty.&lt;h4>Results&lt;/h4>Of the 20 survey respondents, 55% practiced in health care settings affiliated with an academic institution, 45% practiced in a community-based health care setting, and 30% were Endocrinologists. Clinicians in community-based</pubmed_abstract><journal>Transgender health</journal><pubmed_title>Hormone Prescription and HIV Screening/Preventive Practices Among Clinicians Providing Care for Transgender Individuals.</pubmed_title><pmcid>PMC9942173</pmcid><funding_grant_id>P2C HD050924</funding_grant_id><funding_grant_id>K23 HL147799</funding_grant_id><funding_grant_id>K24 AI157882</funding_grant_id><pubmed_authors>Fulda ES</pubmed_authors><pubmed_authors>Toribio M</pubmed_authors><pubmed_authors>Donelan K</pubmed_authors><pubmed_authors>Cetlin M</pubmed_authors><pubmed_authors>Poteat T</pubmed_authors><pubmed_authors>Chu SM</pubmed_authors><pubmed_authors>Gomez Tejeda Zanudo J</pubmed_authors><pubmed_authors>Zanni MV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hormone Prescription and HIV Screening/Preventive Practices Among Clinicians Providing Care for Transgender Individuals.</name><description>&lt;h4>Purpose&lt;/h4>Through a survey-based approach, we sought to investigate regional differences in gender-affirming hormone therapy (GAHT) prescribing practices, as well as HIV screening and prevention practices among clinicians providing care to transgender individuals.&lt;h4>Methods&lt;/h4>Our survey was disseminated between December 2019 and January 2021 to clinicians who prescribe GAHT within New England (United States). Between-group differences in GAHT prescribing and HIV screening/prevention practices were evaluated by practice setting and subspecialty.&lt;h4>Results&lt;/h4>Of the 20 survey respondents, 55% practiced in health care settings affiliated with an academic institution, 45% practiced in a community-based health care setting, and 30% were Endocrinologists. Clinicians in community-based</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-05T00:01:54.917Z</modification><creation>2025-04-05T00:01:54.917Z</creation></dates><accession>S-EPMC9942173</accession><cross_references><pubmed>36824383</pubmed><doi>10.1089/trgh.2021.0118</doi></cross_references></HashMap>